» Articles » PMID: 31618132

Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2019 Oct 17
PMID 31618132
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Most patients with early-stage breast cancer are treated with adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) to prevent locoregional recurrence (LRR). However, no genomic tools are used currently to select the optimal RT strategy.

Methods: We profiled the transcriptome of primary tumors on a clinical grade assay from the SweBCG91-RT trial, in which patients with node-negative breast cancer were randomly assigned to either whole-breast RT after BCS or no RT. We derived a new classifier, Adjuvant Radiotherapy Intensification Classifier (ARTIC), comprising 27 genes and patient age, in three publicly available cohorts, then independently validated ARTIC for LRR in 748 patients in SweBCG91-RT. We also compared previously published genomic signatures for ability to predict benefit from RT in SweBCG91-RT.

Results: ARTIC was highly prognostic for LRR in patients treated with RT (hazard ratio [HR], 3.4; 95% CI, 2.0 to 5.9; < .001) and predictive of RT benefit ( = .005). Patients with low ARTIC scores had a large benefit from RT (HR, 0.33 [95% CI, 0.21 to 0.52], < .001; 10-year cumulative incidence of LRR, 6% 21%), whereas those with high ARTIC scores benefited less from RT (HR, 0.73 [95% CI, 0.44 to 1.2], = .23; 10-year cumulative incidence of LRR, 25% 32%). In contrast, none of the eight previously published signatures were predictive of benefit from RT in SweBCG91-RT.

Conclusion: ARTIC identified women with a substantial benefit from RT as well as women with a particularly elevated LRR risk in whom whole-breast RT was not sufficiently effective and, thus, in whom intensified treatment strategies such as tumor-bed boost, and possibly regional nodal RT, should be considered. To our knowledge, ARTIC is the first classifier validated as predictive of benefit from RT in a phase III clinical trial with patients randomly assigned to receive or not receive RT.

Citing Articles

The potential radiosensitization target PFKFB3 is related to response to radiotherapy in SweBCG91RT: a randomized clinical trial with long-term follow-up.

Egelberg M, De Marchi T, Schultz N, Tran L, Karlsson P, Holmberg E BMC Cancer. 2025; 25(1):374.

PMID: 40022029 PMC: 11869729. DOI: 10.1186/s12885-025-13703-1.


Landscape of the Peripheral Immune Response Induced by Intraoperative Radiotherapy Combined with Surgery in Early Breast Cancer Patients.

Dai D, Li X, Zhuang H, Ling Y, Chen L, Long C Adv Sci (Weinh). 2024; 12(1):e2308174.

PMID: 39494578 PMC: 11714210. DOI: 10.1002/advs.202308174.


Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis.

Karlsson P, Fyles A, Chang S, Arrick B, Baehner F, Malmstrom P J Natl Cancer Inst. 2024; 117(3):486-495.

PMID: 39423142 PMC: 11884857. DOI: 10.1093/jnci/djae262.


Escalation and De-Escalation of Adjuvant Radiotherapy in Early Breast Cancer: Strategies for Risk-Adapted Optimization.

Gruber G Cancers (Basel). 2024; 16(17).

PMID: 39272804 PMC: 11394564. DOI: 10.3390/cancers16172946.


Arginine-solubilized lipoic acid-induced β-sheets of silk fibroin-strengthened hydrogel for postoperative rehabilitation of breast cancer.

Zhang Z, Xia Y, Li X, Zhang Q, Wu Y, Cui C Bioact Mater. 2024; 40:667-682.

PMID: 39257958 PMC: 11386050. DOI: 10.1016/j.bioactmat.2024.08.014.


References
1.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

2.
Slodkowska E, Ross J . MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn. 2009; 9(5):417-22. DOI: 10.1586/erm.09.32. View

3.
Killander F, Anderson H, Kjellen E, Malmstrom P . Increased cardio and cerebrovascular mortality in breast cancer patients treated with postmastectomy radiotherapy--25 year follow-up of a randomised trial from the South Sweden Breast Cancer Group. Eur J Cancer. 2014; 50(13):2201-10. DOI: 10.1016/j.ejca.2014.04.033. View

4.
Mamounas E, Tang G, Fisher B, Paik S, Shak S, Costantino J . Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010; 28(10):1677-83. PMC: 2849763. DOI: 10.1200/JCO.2009.23.7610. View

5.
Zhang W, Mao J, Zhu W, Jain A, Liu K, Brown J . Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy. Nat Commun. 2016; 7:12619. PMC: 5013662. DOI: 10.1038/ncomms12619. View